Celator Pharmaceuticals (CPXX) Misses Q4 EPS by 1c

NDA, MAA Remain Key Focal Points for Celator Pharma (CPXX) Moving Forward; Roth Affirms at 'Buy'

March 21, 2016 11:31 AM EDT

Roth Capital affirms Celator Pharmaceuticals (Nasdaq: CPXX) with a Buy rating and $22 price target after the company announced FY15 results earlier.

Analyst Joseph Pantginis noted that Celator posted FY15 EPS of ($0.57), which compares with the firm's ($0.56) estimate.

Pantginis also commented: With historic data in hand and a significantly de-risked program, in... More

Top 10 News for 3/14 - 3/18: Valeant Outlook Spooks Wall St.; Chipotle Troubles Continue; Fed Sees Two Hikes in 2016

March 18, 2016 3:52 PM EDT

1. Valeant Pharma (NYSE: VRX) shares were hit this week after the company reported Q4 EPS of $2.50 with revenue of $2.8 billion. The Street was looking for EPS of $2.61 and revenue of $2.75 billion. In addition, Valeant lowered its FY16 outlook and guidance for the next four quarters. Shares are down over 60 percent on the week.

2. The Fed offered a statement from the FOMC's March 15th - 16th meeting.... More

Steve Cohen’s Point72 says it has perfect U.S. compliance

March 17, 2016 7:42 PM EDT

By Lawrence Delevingne and Jennifer Ablan

NEW YORK (Reuters) - Billionaire Steve Cohen's investment firm, a family office that took over managing his fortune in 2014 after his hedge fund pleaded guilty to securities fraud, has a perfect regulatory compliance record, its president said on Thursday.

Point72 Asset Management, which manages about $11 billion and took over after regulators barred Cohen's SAC Capital Advisors from dealing with the public, has had zero point zero compliance and regulatory problems, Point72 President Doug Haynes said in an interview.

The firm succeeded SAC Capital Advisors, Cohen's hedge fund firm which pleaded guilty... More